Targets › ITK
3 programs from 2 companies in 16 trials: 7 Phase 3, 7 Phase 2, 2 Phase 1; Immunology, Oncology, Metabolic and endocrine; next expected readout Dec 2026.
Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. (UniProt, Q08881)
Open in Phaseline: the race on ITK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Ritlecitinib Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor | JAK3, ITK, BMX, TEC, TXK | Phase 3 | Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata … | Dec 2026 |
| Corvus Pharmaceuticals | Soquelitinib ITK inhibitor | ITK | Phase 3 | Peripheral T-Cell Lymphoma, Not Otherwise Specified; Atopic Dermatitis; Hidradenitis Suppurativa (HS); Autoimmune Lymphoproliferative Syndrome | Jun 2027 |
| Corvus Pharmaceuticals | CPI-818 Interleukin-2 inducible T-cell kinase (ITK) inhibitor | ITK | Phase 1 | T-cell Lymphoma | Dec 2026 |
Severe Alopecia Areata (2) Vitiligo (2) Alopecia Areata (2) Peripheral T-Cell Lymphoma, Not Otherwise Specified (1) Atopic Dermatitis (1) Hidradenitis Suppurativa (HS) (1) Autoimmune Lymphoproliferative Syndrome (1) Stable Nonsegmental Vitiligo (1) Hidradenitis Suppurativa (1) Chronic Spontaneous Urticaria (1) Keloid (1) Diabetes Mellitus, Type 1 (1)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.